We are focused on advancing targeted therapeutic approaches for aggressive cancers, beginning with glioblastoma. Our strategy is centered on identifying innovative solutions that address significant unmet needs and have the potential to improve outcomes for patients facing limited treatment options.

• Patient-focused innovation
• Scientific rigor
• Targeted therapeutic development
• Long-term commitment to oncology research